#investing / Page 4

EyePoint Pharmaceuticals secures $140M through public offering at $11/share, fueling development of DURAVYU eye treatment. See how this biotech deal impacts investors and patients.

These three high-yield dividend stocks could be excellent buys for income-seeking investors amid falling interest rates.

US dollar rally pauses before jobs data, Aussie droops on RBA outlook ...

Kolibri Energy launches strategic share buyback program with Roth Capital, enabling automated purchases during restricted periods. Learn how this plan affects investor value and market stability.

Buying these two attractive growth stocks now can help you ride the wave of the TSX's record-breaking rally and maximize your long-term portfolio's growth potential.

I am likely buying Air Canada (TSX:AC) stock in 2025.

Newell Brands secures $1.25B in new notes at 6.3-6.6% interest, restructuring debt to extend maturities through 2032. Learn how this strategic refinancing impacts the company's financial outlook despite higher rates. $NWL ...

Nordson's award-winning SL-1040 coating system revolutionizes electronics manufacturing with advanced protection technology. Discover how this innovative solution enhances production efficiency and device durability.

Shuttle Pharmaceuticals secures $4.5M through public offering to advance cancer drug trials, with $2.3M allocated for Phase II testing of Ropidoxuridine. Learn how this strategic funding impacts drug development timelines.

Australia Q3 inflation slows to 3-1/2-year low, core more stubborn ...